此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

新型眼镜镜片的安全性和近视加深控制评价

2026年9月15日 更新者:HOYA Lens Thailand LTD.

The goal of this clinical trial is to test Novel spectacle lenses in myopic children. The main question it aims to answer are: safety and efficacy of the lenses. Participants will be asked to wear spectacles and participate in eye exams and questionnaires. Researchers will compare Novel spectacle lenses and general single vision spectacle lenses to see if the Novel spectacle lenses correct myopic ametropia, slow the progression of myopia and axial elongation.

研究概览

详细说明

This is a 3-year prospective, multicenter, randomized, and single-masked*, parallel-group controlled clinical study. The purpose of this study is to evaluate the safety and efficacy of wearing Novel spectacle lenses to correct myopic ametropia, slow the progression of myopia and axial elongation in myopic children as compared to the use of single vision spectacles lenses.

The treatment arms are:

  • Model A Novel spectacle lens
  • Model B Novel spectacle lens
  • Single vision spectacle lens

Single-masked:

The investigator responsible for conducting ocular data measurements related to the primary and secondary endpoints will be masked. The participants will not be informed the treatment arm during the clinical trial.

研究类型

介入性

注册 (实际的)

249

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国
        • Beijing Tongren Hospital, Capital Medical University
      • Guangzhou、中国
        • Guangzhou Aier Eye Hospital
      • Shanghai、中国
        • Eye and ENT Hospital of Fudan University
      • Shengyang、中国
        • Shengyang He Eye Specialist Hospital
      • Tianjin、中国
        • Tianjin Medical University Eye Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

7年 至 13年 (孩子)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participant and parent (or guardian) are able and willing to provide consent
  2. Participant and parent (or guardian) ensure to attend required study visits and adhere to participant requirements
  3. Parent or guardian understands and accepts random allocation of grouping, and that participant and parent (or guardian) will not be told which group participant is allocated to
  4. Participant willing to wear the study spectacles lens for a minimum of 12 hours per day for the duration of the study
  5. Age at time of parent or guardian consent and participant assent: 7 - 13 years old
  6. Spherical equivalent cycloplegic autorefraction: -1.00 to -7.00 D in each eye.
  7. Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye
  8. Cycloplegic autorefraction anisometropia of 1.50 D or less
  9. Monocular best corrected distance visual acuity (BCDVA) equal to or better than logMAR 0.10 in each eye.

Exclusion Criteria:

  1. Participant is allergy to fluorescein, benoxinate, proparacaine, tropicamide or cyclopentolate eye drops
  2. Any ocular and systemic abnormalities might be expected to affect visual functions or refractive development
  3. (a) Have received treatment of myopic control pharmaceutical medication (e.g., atropine) or light fundus illuminance therapy (e.g., repeated red light therapy) within 6 months prior to entry into this study. (b) Have received treatment of myopia control such as contact lenses, orthokeratology lenses etc., progressive addition lenses, bifocal lenses, within 3 months. (c) Have received treatment of myopia control such as defocus spectacle lenses (difference between both eye's non-cycloplegic autorefraction and lens-meter results of the respective lenses are equal or less than 0.50 D SER) etc. within one month prior to entry into this study.
  4. Participant with clinically significant strabismus (including intermittent tropia)
  5. Medical history of binocular vision abnormalities
  6. Participant with amblyopia
  7. Participation in a clinical trial within 30 days prior to entry into this study or during participation
  8. Previous intraocular surgery
  9. Participant who, in the judgment of the Investigator, presence of any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.
  10. Any medical treatment or medication which might have an influence on vision or interfere with study assessments
  11. Pathological myopia (myopia that leads to structural changes in the posterior segment of the eye including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Model-A新型眼镜片

Model-A Novel spectacle lenses will be given to 1 arm to wear for 36 months

实验性的:B型新型眼镜镜片

Model-B Novel spectacle lenses will be given to 1 arm to wear for 36 months

其他:单光眼镜镜片

Single Vision Spectacle lenses will be given to 1 arm to wear for 36 months

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Axial length
大体时间:24 months

The difference of Axial length changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants.

24 months
Spherical equivalent cycloplegic autorefraction
大体时间:24 months

The difference of spherical equivalent cycloplegic autorefraction changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants

24 months

次要结果测量

结果测量
大体时间
轴向长度
大体时间:36个月
36个月
球面等效睫状麻痹自动验光
大体时间:36个月
36个月

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年7月31日

初级完成 (实际的)

2026年7月25日

研究完成 (估计的)

2027年5月31日

研究注册日期

首次提交

2023年5月23日

首先提交符合 QC 标准的

2023年5月23日

首次发布 (实际的)

2023年6月2日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2026年3月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • DG2-3A

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅